Clinical trials: Menopausal Osteoporosis
Postmenopausal Women With Osteoporosis
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.
- Trial name
- ARCH (NCT01631214)
- Testing
- Romosozumab, Alendronate
- Where
- 316 sites in United States, Argentina and 40 more
- Volunteers
- 4,093 people
- Sponsor
- Amgen
Periodontal Disease, Postmenopausal Osteoporosis (PMO)
Relationship Between Periodontal Disease and Postmenopausal Osteoporosis
Elevated sclerostin levels in serum and alveolar bone of osteoporotic patients may exert deleterious effects on the periodontium, thereby contributing to the progression and increased severity of periodontal disease.
- Trial name
- NCT07294105
- Testing
- clinical assessment, Radiographic Evaluation
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Recep Tayyip Erdogan University
Osteoporosis, Post-Menopausal
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial
- Trial name
- NCT00532246
- Testing
- raloxifene
- Where
- 5 sites in United States
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan
This observational study will provide an opportunity to document local patterns of susceptibility, patient profile, and usefulness of screening in postmenopausal patients coming to gynecology outpatient clinics in Pakistan.
- Trial name
- NCT02422069
- Where
- 8 sites in Pakistan
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Postmenopausal
A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
This study will evaluate whether the once weekly administration of the combination tablet alendronate/vitamin D3 (FOSAMAX PLUS) will increase lumbar spine bone mineral density (BMD) more than the daily use of calcitriol.
- Trial name
- NCT01350934
- Testing
- alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus), Calcitriol, Calcium 500 mg
- Volunteers
- 219 people
- Sponsor
- Organon and Co
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Osteoporosis
Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis
Osteoporosis is characterized by decreased bone strength and it is prevalent among postmenopausal women but also occurs in men and women with underlying conditions or major risk factors associated with bone demineralization.
- Trial name
- NCT01760798
- Testing
- Teriparatide
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Osteoporosis, Postmenopausal
A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
The purpose of this study is to see how well alendronate and calcium as compared to calcium alone increase bone density in postmenopausal women with osteoporosis
- Trial name
- NCT00398606
- Testing
- MK0217, alendronate sodium / Duration of Treatment : 2 Years, Comparator : calcium carbonate /Duration of Treatment : 2 Years
- Volunteers
- 650 people
- Sponsor
- Organon and Co
Osteoporosis, Postmenopausal
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether…
- Trial name
- NCT00046137
- Testing
- teriparatide, raloxifene
- Where
- 13 sites in United States
- Sponsor
- Eli Lilly and Company
Osteoporosis Postmenopausal
Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
The purpose of this study is to assess the dose-response on the percent change from baseline in lumbar spine bone mineral density (BMD) at lumbar vertebrae 1 to 4 (L1- L4) when odanacatib (MK-0822) 10 mg, 25 mg, 50 mg or placebo…
- Trial name
- NCT00620113
- Testing
- Odanacatib, Vitamin D3, Calcium carbonate
- Volunteers
- 287 people
- Sponsor
- Merck Sharp & Dohme LLC
Low Bone Mineral Density, Postmenopausal Osteoporosis
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low…
- Trial name
- NCT00896532
- Testing
- Alendronate, Teriparatide, Romosozumab
- Volunteers
- 419 people
- Sponsor
- Amgen
Menopausal Syndrome, Cardiovascular Disease
Multi-centre Clinical Trial on Hormone Replacement Treatment in China
This study is to evaluate the benefit/risk of hormone replacement treatment among early menopausal women in China. This is a multi-centre, random, prospective study.
- Conditions
- Menopausal Syndrome, Cardiovascular Disease, Osteoporosis, Breast Cancer
- Trial name
- NCT01698164
- Testing
- estradiol plus MPA, Ximingting Tablet, estradiol plus progesterone
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Peking Union Medical College Hospital
Postmenopause, Osteoporosis
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
The objectives of the study are to describe the quality of life at the beginning of the Preotact® treatment and at the end of the observational period (Qualeffo-41 questionnaire) pain assessment at the beginning of the Preotact®…
- Trial name
- NCT00515593
- Testing
- Parathyroid hormone (PTH) (Preotact)
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Nycomed
Osteoporosis
A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.
- Trial name
- NCT00471237
- Testing
- Ronacaleret, Teriparatide, Alendronate
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 564 people
- Sponsor
- GlaxoSmithKline
Osteoporosis, Postmenopausal
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
The primary objective of this study is to demonstrate a reduction in the proportion of new vertebral fractures in postmenopausal women with osteoporosis following 3-years of treatment with 20 and 40 mcg/day of teriparatide plus…
- Trial name
- NCT00670501
- Testing
- teriparatide, Calcium Supplement, Vitamin D Supplement
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,637 people
- Sponsor
- Eli Lilly and Company
Osteoporosis, Postmenopausal, Balance; Distorted
Validity of Korebalance Balance System
In postmenopausal osteoporosis patients, the balance is impaired. Equilibrium is evaluated with various test and balance systems.
- Trial name
- NCT03832075
- Testing
- Berg Balance Scale, Timed Up and Go Test, Korebalance Balance System
- Where
- Turkey (Türkiye)
- Volunteers
- 53 people
- Sponsor
- Istanbul Medeniyet University
Osteoporosis, Postmenopausal
ValoRization of Dairy Sidestreams to Fight Calcium dEficits iN Postmenopausal Women
The primary objective of this study is to investigate the effects of 12-months supplementation with calcium-enriched permeate, taken alone or in conjunction with inulin, on changes in markers of bone formation and resorption and…
- Trial name
- RENEW (NCT04836637)
- Testing
- Maltodextrin, Calcium-carbonate, Calcium-enriched permeate
- Where
- 2 sites in Denmark
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Osteoporosis, Osteoporosis, Postmenopausal
3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women
The main purpose of this study is to determine the safety and effectiveness of three week daily subcutaneous injections of Parathyroid Hormone-related Protein (1-36).
- Trial name
- NCT00222872
- Testing
- Parathyroid Hormone-related Protein
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Bone Loss
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
- Trial name
- LACE (NCT00674453)
- Testing
- Lasofoxifene
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Ligand Pharmaceuticals
Postmenopausal Osteoporosis
Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women
This is a phase I study to analyze bioavailability and pharmacodynamic of two different variants of oral salmon calcitonin (SMC021) in postmenopausal women
- Trial name
- NCT00411125
- Testing
- Oral salmon calcitonin
- Where
- Denmark
- Volunteers
- 86 people
- Sponsor
- Novartis